GlassScriptPhysician profile
Erin I Marquez
NPI 1992412290
$3,630.53
in general payments reported to CMS, 2019-2025
44 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $356 · 2024: $1,536 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.76 | 2023-2025 | |
| Pfizer INC. | $378.19 | 2023-2025 | |
| Abiomed | $209.16 | 2024-2025 | Impella |
| Novo Nordisk INC | $199.09 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $192.67 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $170.16 | 2024-2025 | Rexulti |
| Amgen INC. | $159.75 | 2023-2024 | Repatha, Otezla, Tezspire |
| Astrazeneca Pharmaceuticals LP | $144.49 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.54 | 2023-2025 | Jardiance |
| Axsome Therapeutics, INC. | $120.25 | 2024-2025 | Auvelity, Sunosi |
| Astellas Pharma US INC | $110.14 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $97.40 | 2023-2025 | Verquvo, Belsomra |
| Xeris Pharmaceuticals, INC. | $87.01 | 2025 | Recorlev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.20 | 2024-2025 | Caplyta |
| Shield Therapeutics INC | $85.06 | 2024-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $71.58 | 2024-2025 | Rexulti |
| Antares Pharma, INC. | $57.87 | 2025 | Xyosted |
| Verity Pharmaceuticals INC. | $56.37 | 2025 | Tlando |
| Viatris Specialty LLC | $56.11 | 2025 | Yupelri |
| Mayne Pharma Commercial LLC | $48.06 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $47.90 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.87 | 2024 | |
| Organon LLC | $41.61 | 2023-2025 | Nexplanon |
| Vanda Pharmaceuticals INC. | $41.59 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $37.19 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $33.91 | 2023-2024 | Trintellix |
| Nalu Medical, INC. | $32.02 | 2025 | Nalu Neurostimulation System |
| Recordati_rare_diseases_inc. | $30.61 | 2025 | Isturisa |
| Tempus Ai, INC | $26.62 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $26.56 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $24.99 | 2024 | Injectafer |
| Hologic Sales and Service, LLC | $24.69 | 2024 | Thinprep 2000 Processor |
| Mylan Specialty L.P. | $23.76 | 2023 | Yupelri |
| Qiagen, LLC | $20.26 | 2023 | Quantiferon-Tb Gold Plus |
| Optinose US, INC. | $18.63 | 2024 | |
| Agile Therapeutics, INC. | $18.52 | 2024 | Twirla |
| Corcept Therapeutics | $18.43 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $18.38 | 2023 | Trelegy Ellipta |
| Seqirus USA INC | $17.09 | 2025 | Flucelvax, Fluad |
| Neurocrine Biosciences, INC. | $17.01 | 2024 | |
| Dexcom, INC. | $15.40 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $15.30 | 2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $14.54 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $13.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.